Sanatan Majhi

Sanatan Majhi


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2019 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
Rout George KerryRout George Kerry
Rout George Kerry
SMSantosh Malik
Santosh Malik
YRYisehak Tsegaye Redda
Yisehak Tsegaye Redda
SSSabuj Sahoo
Sabuj Sahoo
Jayanta Kumar PatraJayanta Kumar Patra
Jayanta Kumar Patra
SMSanatan Majhi
Sanatan Majhi

5 October 2022 in Environmental Science and Pollution Research
Verified
Journal Article
Closed access
PDF file
Rout George KerryRout George Kerry
Rout George Kerry
FMFrancis Jesmar Perez Montalbo
Francis Jesmar Perez Montalbo
RDRajarshi Das
Rajarshi Das
SPSushmita Patra
Sushmita Patra
GMGyana Prakash Mahapatra
Gyana Prakash Mahapatra
JRJyoti Ranjan Rout
Jyoti Ranjan Rout

7 March 2022 in Journal of Inorganic and Organometallic Polymers and Materials
Verified
Journal Article
Closed access
PDF file
RKRout George Kerry
Rout George Kerry
PMPriyanka Mohapatra
Priyanka Mohapatra
Atala Bihari jenaAtala Bihari jena
Atala Bihari jena
BPBijayananda Panigrahi
Bijayananda Panigrahi
KPKahnu Charan Pradhan
Kahnu Charan Pradhan
Jayanta Kumar PatraJayanta Kumar Patra
Jayanta Kumar Patra

30 June 2023 in INNOSC Theranostics and Pharmacological Sciences
Verified
Journal Article
Open access
PDF file
PDPoonam Das
Poonam Das
SSSabuj Sahoo
Sabuj Sahoo
SMSanatan Majhi
Sanatan Majhi
RKRout George Kerry
Rout George Kerry
ASANUP SINGH
ANUP SINGH
Atala Bihari jenaAtala Bihari jena
Atala Bihari jena
The present work was designed to investigate the antiviral potential of novel monomeric and oligomeric chitosan derivatives through in silico approaches. The goal was to identify potent broad-spectrum antiviral compounds as promising drug candidates against severe acute respiratory syndrome coronavirus 2 and understand their mode of action. Chitosan biopolymer and its derivatives were virtually screened against the spike glycoprotein and human angiotensin-converting enzyme 2 (ACE2) receptor of novel coronavirus-19. Hydroxypropyl trimethyl ammonium chloride chitosan (HTCC), a polymeric chitosan, has been reported to interact with the corona viral spike (S) protein and blocks its interaction with the ACE2 receptor. The enhancement of antiviral activity relies on better biocompatibility, structural correlations, variation in the degree of deacetylation, and molecular weight of modified chitosan derivatives. The chitosan derivatives constructively interact with viral S protein. Among the chitosan derivatives, N-carboxymethyl chitosan (NCMC) displayed efficient binding affinity. Comparing NCMC to mHTCC, monomeric chitosan, for their interaction with the S protein, receptor binding domain site, and ACE2 receptor, NCMC displayed better binding affinity of −7.9, −6.3, and −7.4 with binding energies of −6.2, −4.8, and −5.5 kcal/mol, respectively. Furthermore, through flexible docking, the interactions of the S protein with ACE2 receptor and ligand mHTCC-S protein complex and NCMC-S protein complex with ACE2 receptor were calculated, showing an efficient reduction of binding energy from −901.2 kJ/mol to −765.06 kJ/mol and −814.72 kJ/mol, respectively. This points to the decrease binding affinity of the viral S protein for the ACE2 receptor in the presence of NCMC/mHTCC. For the first time, the computational study envisages the antiviral efficiency of NCMC, mHTCC, and biocompatible chitosan derivatives as a preventive intervention against COVID-19.

24 April 2025 in In Silico Pharmacology
Verified
Journal Article
Closed access
PDF file
RKRout George Kerry
Rout George Kerry
SMSoumya Ranjan Mahapatra
Soumya Ranjan Mahapatra
SNSanghamitra Nayak
Sanghamitra Nayak
HNHemangini Naik
Hemangini Naik
KKKanika Kisku
Kanika Kisku
SMSanatan Majhi
Sanatan Majhi

7 June 2022 in Preprints.org
Verified
Preprint
Open access
PDF file
PDPoonam Das
Poonam Das
SSSabuj Sahoo
Sabuj Sahoo
SMSanatan Majhi
Sanatan Majhi
Rout George KerryRout George Kerry
Rout George Kerry
Atala Bihari jenaAtala Bihari jena
Atala Bihari jena
The present work was designed to investigate antiviral potential of novel mono and oligomeric Chitosan derivatives through in-silico approaches to find potent broad-spectrum anti-viral and promising drug candidates against SARS-CoV-2 and augmentation of their mode of action. Chitosan biopolymer and its derivatives were screened virtually against spike glycoprotein and human ACE2 receptor of nCoV-19. HTCC a polymeric Chitosan has been reported to interact with the corona viral Spike (S) protein and blocks its interaction with ACE2 receptor. Better biocompatibility, structural correlations, variation in degree of decetylation and molecular weight of modified Chitosan derivatives are the key attributes for enhancement of anti-viral activity. The Chitosan derivatives constructively interact with viral S protein. N-Carboxy methyl Chitosan (NCMC) among the Chitosan derivatives displayed efficient binding affinity. NCMC, when compared to mHTCC, a monomeric Chitosan for its interaction with the S protein, RBD site and ACE2 receptor, displayed efficient binding affinity with binding energy of -7.9, -6.3 and -7.4; -6.2, -4.8 and -5.5 Kcal/mol respectively. The interaction of S protein with ACE2 and ligand mHTCC-S protein complex and NCMC-S protein complex with ACE2 was calculated through flexible docking resulted in efficient reduction of binding energy from -901.2kJ/mol to -765.06kJ/mol and-814.72kJ/mol respectively, elucidated that the binding affinity of the viral S protein for its receptor ACE2 decreases in the presence of NCMC/mHTCC. The computational study envisages the antiviral efficiency of NCMC, mHTCC and biocompatible Chitosan derivatives for the first time,as preventive intervention against Covid-19.